⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BLSM News
BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
globenewswire.com
BLSM
Form 8-K
sec.gov
BLSM
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
globenewswire.com
BLSM
Form 8-K
sec.gov
BLSM
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
globenewswire.com
BLSM
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
BLSM
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
globenewswire.com
BLSM
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
globenewswire.com
BLSM
Form 8-K
sec.gov
BLSM